Q2 2016 13F Holders as of 6/30/2016
-
Type / Class
-
Equity / Common Shares, No Par Value
-
Shares outstanding
-
28.5M
-
Number of holders
-
22
-
Total 13F shares, excl. options
-
1.58M
-
Shares change
-
-74.1K
-
Total reported value, excl. options
-
$5.62M
-
Value change
-
-$382K
-
Number of buys
-
8
-
Number of sells
-
-18
-
Price
-
$3.56
Significant Holders of Oncocyte Corporation - Common Shares, No Par Value (OCX) as of Q2 2016
32 filings reported holding OCX - Oncocyte Corporation - Common Shares, No Par Value as of Q2 2016.
Oncocyte Corporation - Common Shares, No Par Value (OCX) has 22 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 1.58M shares
of 28.5M outstanding shares and own 5.54% of the company stock.
Largest 10 shareholders include BROADWOOD CAPITAL INC (1.09M shares), BRIDGEWAY CAPITAL MANAGEMENT INC (100K shares), VANGUARD GROUP INC (89K shares), BlackRock Institutional Trust Company, N.A. (69.2K shares), Manatuck Hill Partners, LLC (68.5K shares), Artal Group S.A. (64.1K shares), GOLDMAN SACHS GROUP INC (29.6K shares), Destination Wealth Management (20.7K shares), GEODE CAPITAL MANAGEMENT, LLC (15K shares), and Paloma Partners Management Co (11.8K shares).
This table shows the top 22 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.